Perioperative very late stent thrombosis treated with thrombosuction.
نویسندگان
چکیده
Fig. 1: Left coronary angiogram in Right Anterior Oblique view with caudal tilt showing thrombus inside the Left Anterior Descending ( LAD) stent at diagonal origin .Note the haziness marked by arrow , indicating a filling defect inside the stent . LCX= Left circumflex , LMCA= Left Main Coronary Artery ,OM = Obtuse Marginal. Fig. 2: Post thrombosuction left coronary angiogram in the same view shows that the filling defect has disappeared. Abbreviations are as in the previous figure. INTRODUCTION With widespread use of Drug Eluting Stents (DES), perioperative dual antiplatelet issues are becoming more frequent. The risk of perioperative bleeding needs to be balanced against the devastating complication of stent thrombosis since mortality rates for stent thrombosis range from 20% to 45%. Usually these issues are a concern within the first year after stent implantation . We report a case where perioperative withdrawl of dual antiplatelets prior to a non-cardiac surgery lead to stent thrombosis and cardiogenic shock, five years post implantation .
منابع مشابه
Successful treatment of perioperative very late stent thrombosis with thromboaspiration device.
I read with interest the article by S Sikdar et al on “Perioperative Very Late Stent Thrombosis treated with Thrombosuction” . The authors highlighted a very pertinent issue regarding the perioperative management conundrum of antiplatelet therapy in the setting of prior coronary stent implantation. Cypher ® (Cordis, Johnson & Johnson, Bridgewater, NJ) is a sirolimus drug eluting stent. As point...
متن کاملLate thrombosis of a drug-eluting stent presenting in the perioperative period.
DRUG-ELUTING stents (DES) represent the latest percutaneous coronary intervention (PCI) designed to deal with the problem of in-stent restenosis. These stents are impregnated with a drug (sirolimus or paclitaxel) that retards the neointimal proliferation that leads to restenosis. The thrombogenic profile of DES differs from that of bare metal stents. Postprocedure dual antiplatelet therapy (clo...
متن کاملMeta-analysis of stent thrombosis after drug-eluting stent implantation: 4-year follow-up.
BACKGROUND Drug-eluting stents (DES) are the most common device used in percutaneous treatment of coronary artery disease. Recently, there has been an increased concern regarding their safety profile, in particular the late and very late stent thrombosis rate compared to bare metal stents (BMS). The aim of the study was to compare the reported incidence of late and very late stent thrombosis of...
متن کاملUse of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: intermediate- to long-term clinical follow-up.
AIMS We assessed the use of the endothelial progenitor cell (EPC) capture stent in primary percutaneous intervention in ST-elevation myocardial infarction (STEMI). METHODS AND RESULTS One hundred and twenty patients with acute STEMI without cardiogenic shock received 129 EPC capture stents. Procedural success was achieved in 95% of patients. Dual antiplatelet therapy was given for a month and...
متن کاملThe risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents.
OBJECTIVES We aimed to evaluate the risk of definite stent thrombosis with bare-metal stents (BMS) and drug-eluting stents (DES) in patients treated for acute coronary syndromes. BACKGROUND Acute coronary syndromes (ACS) have been reported as increasing the risk for stent thrombosis. METHODS Between January 2000 and December 2005, 5,816 consecutive patients underwent percutaneous coronary i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Medical journal of Malaysia
دوره 67 1 شماره
صفحات -
تاریخ انتشار 2012